David Johnson, CEO of Alliqua, Inc.
David Johnson was President of the ConvaTec division of Bristol-Myers Squibb until 2008 when he orchestrated a sale of the division from its pharmaceutical parent to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion. Concurrently, he acquired and integrated the assets of Copenhagen-based Unomedical to expand ConvaTec Inc.’s manufacturing and infrastructure into Europe.
From 2008 through 2012, Mr. Johnson served as the Chief Executive Officer of ConvaTec Inc. Prior to his tenure with ConvaTec Inc., Mr. Johnson held several senior positions in the U.S., Europe and Canada with Zimmer Inc., Fisher Scientific, and Baxter Corporation. He served as a member of ConvaTec Inc.’s Board of Directors and the Board of the Advanced Medical Technology Association (AdvaMed), where he chaired the Global Wound Sector Team for four years. Mr. Johnson received an undergraduate business degree in marketing from the Northern Alberta Institute of Technology in Edmonton, Alberta, Canada, completed the INSEAD Advanced Management Program in Fontainbleau, France, and is a fellow from the Wharton School of the University of Pennsylvania.
Brian M. Posner, Chief Financial Officer of Alliqua, Inc.
Brian Posner is a strategic and financial leader with more than 25 years of diversified management experience, working in both public and private companies ranging from startup to $1B in revenue. Most recently he served as CFO of Ocean Power Technologies, Inc., a pioneer in wave-energy technology. Prior to that appointment, he served as CFO of Power Medical Interventions, Inc. until its sale to Covidien plc in 2009. He earlier served as CFO of Pharmacopeia, Inc. and Phytomedics, Inc., and as Regional CFO of Omnicare, Inc. Mr. Posner is a Certified Public Accountant and earned an MBA in Managerial Accounting from Pace University’s Lubin School of Business and a BA in Accounting from Queens College.
Brad C. Barton, Chief Operating Officer of Alliqua, Inc.
Brad Barton was formerly the President of ConvaTec Americas with responsibility for all ConvaTec businesses in the U.S., Canada, and Latin America. During his time at ConvaTec, Mr. Barton led the team responsible for the acquisition and integration of 180 Medical and Abviser. Mr. Barton was instrumental in helping to establish Convatec as a standalone company in the Americas and also helped transition the Company after its sale to Nordic Capital and Avista Capital Partners.
Prior to his America’s role, Mr. Barton had responsibilities for ConvaTec’s business in China, Asia, Japan, and Australia. Other senior roles at ConvaTec helped Mr. Barton hone his extensive knowledge of U.S. distribution channels, GPO’s, and the post acute care market segment. Mr. Barton has held a number of sales leadership roles at Calgon Corp. and Vestal Laboratories.
Lori Toner, Chief Marketing Officer of Alliqua, Inc.
Lori Toner was Vice President of Global Marketing at ConvaTec’s Wound Therapeutics division until 2012. In this role, Ms. Toner led a global team responsible for $500M+ in annual revenues. Specific responsibilities included strategic planning, product development, product launches, and marketing.
Prior to leading Global Marketing at ConvaTec, Ms. Toner held several other sales and marketing leadership roles at ConvaTec. Ms. Toner acted as the Interim Leader for Unomedical, a $600M Continence and Critical Care company with 4,500 employees; the acquisition of Unomedical substantially expanded ConvaTec’s reach in Europe, Asia, and Australia. Ms. Toner also served as the Vice President of Global Selling Effectiveness, where she designed strategies to enhance sales and marketing returns, while ensuring consistent operating procedures for a 1,500 member team.
Dr. Janice M. Smiell, M.D., Chief Medical Officer of Alliqua, Inc.
Dr. Janice Smiell, M.D. brings over twenty years of wound care, regenerative medicine, and clinical development experience to Alliqua. She is the former VP of Medical Affairs at LifeCell Corporation, where she oversaw clinical development and product safety programs from 2007 to 2011. LifeCell develops and markets tissue repair products for use in reconstructive, urogynecologic, and orthopedic surgical procedures. Prior to joining LifeCell, Dr. Smiell was the Executive Director of Global Clinical R&D at Celgene, where she led the clinical development of biomaterials and stem cells at the Company’s Cellular Therapeutics Division.
From 1994 to 2003, Dr. Smiell was the Senior Director of Global Clinical R&D at Johnson and Johnson where she was awarded the prestigious Johnson Medal in recognition of her development work on Regranex, a growth factor for wound healing. Before joining Johnson and Johnson, Dr. Smiell served as the Medical Director of the Wound Care Center at Morristown Memorial Hospital. Dr. Smiell received her M.D. from the Medical College of Pennsylvania in Philadelphia (now Drexel University School of Medicine).
Gregory Robb, VP Operations of AquaMed Technologies, Inc.
Gregory Robb has over 20 years of experience working with and manufacturing electron beam cross-linked hydrogels. Mr. Robb coordinated and supervised the construction of the AquaMed facility and has overseen product development, production, process improvements, while also serving as the primary point of customer contact.
Prior to joining AquaMed, Mr. Robb was the Project Engineer and Facility Manager at E-Beam Services, where he was responsible for the expansion of the business, including the installation of a 10 MeV linear accelerator. Mr. Robb holds a Bachelor of Science degree in Mechanical Engineering from Trenton State College.